MetaVia

MetaVia EBITDA Growth YoY

The Year-over-Year EBITDA Growth of MetaVia (MTVA) as of Oct 27, 2026 is 52.42 %. In the previous year, Year-over-Year EBITDA Growth was -81.35 % — a change of -164.44% (higher).

EBITDA Growth YoY

52.42 %

YoY

-164.44%

Last updated:

Year-over-Year EBITDA Growth of MetaVia is 2025 52.42 % . Year-over-Year EBITDA Growth of MetaVia was 2024 -81.35 % . It decreases by -164.44% higher compared to the previous year.

The MetaVia EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
53.25 USD
Jan 1, 2019
-30.29 USD
Jan 1, 2020
-47.28 USD
Jan 1, 2021
48.52 USD
Jan 1, 2022
-28.30 USD
Jan 1, 2023
19.06 USD
Jan 1, 2024
-81.35 USD
Jan 1, 2025
52.42 USD
The MetaVia EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
52.42 %-164.44%
-81.35 %-526.70%
19.06 %-167.36%
-28.30 %-158.34%
48.52 %-202.61%
-47.28 %+56.13%
-30.29 %-156.88%
53.25 %-142.46%
-125.39 %+52.97%
-81.97 %-97.21%
-2,936.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

Year-over-Year EBITDA Growth of MetaVia is 52.42 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth MetaVia since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's MetaVia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — MetaVia

All Key Metrics — MetaVia